LLY · News · 20260922N

Manufacturing Capacity - Foundayo

ELI LILLY & Co · 2026-09-22 · Importance 52 · Surprise 42

Eli Lilly is rapidly expanding manufacturing capacity for the oral obesity treatment Foundayo, which management says is capturing a significant share of new GLP-1 prescriptions. Lilly is building a $6.5 billion facility in Houston to produce Foundayo’s active ingredient, with operations targeted for 2030. The company also plans to introduce Foundayo in additional international markets. The article cites potential demand expansion into type 2 diabetes and possible Medicare coverage for obesity treatments.

Key facts